International Orthopaedics

, Volume 37, Issue 4, pp 583–587

Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?

Authors

  • Jaap J. Brunnekreef
    • Department of OrthopaedicsRadboud University Nijmegen Medical Centre
  • Paul Hoogervorst
    • Department of OrthopaedicsRadboud University Nijmegen Medical Centre
  • Marieke J. Ploegmakers
    • Department of RadiologyRadboud University Nijmegen Medical Centre
  • Wim H. Rijnen
    • Department of OrthopaedicsRadboud University Nijmegen Medical Centre
    • Department of OrthopaedicsRadboud University Nijmegen Medical Centre
Original Paper

DOI: 10.1007/s00264-013-1781-0

Cite this article as:
Brunnekreef, J.J., Hoogervorst, P., Ploegmakers, M.J. et al. International Orthopaedics (SICOT) (2013) 37: 583. doi:10.1007/s00264-013-1781-0

Abstract

Purpose

Heterotopic ossification is a common complication after total hip arthroplasty. Non-steroidal anti-inflammatory drugs (NSAIDs) are known to prevent heterotopic ossifications effectively, however gastrointestinal complaints are reported frequently. In this study, we investigated whether etoricoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor that produces fewer gastrointestinal side effects, is an effective alternative for the prevention of heterotopic ossification.

Methods

We investigated the effectiveness of oral etoricoxib 90 mg for seven days in a prospective two-stage study design for phase-2 clinical trials in a small sample of patients (n = 42). A cemented primary total hip arthroplasty was implanted for osteoarthritis. Six months after surgery, heterotopic ossification was determined on anteroposterior pelvic radiographs using the Brooker classification.

Results

No heterotopic ossification was found in 62 % of the patients that took etoricoxib; 31 % of the patients had Brooker grade 1 and 7 % Brooker grade 2 ossification.

Conclusions

Etoricoxib seems effective in preventing heterotopic ossification after total hip arthroplasty. This finding further supports the use of COX-2 inhibitors for the prevention of heterotopic ossification following total hip arthroplasty.

Copyright information

© Springer-Verlag Berlin Heidelberg 2013